EL7.AI
StocksMedium•19 November 2026•
4 min read

Medicure posts C$1.3 million net loss and C$7.9 million in revenue in third quarter

Key Facts

1The net loss was C$1.3 million, or $0.13 per share, compared with $1.4 million and $0.13 per share a year earlier.
2Net revenue reached C$7.9 million, compared with C$8.2 million in the third quarter of 2025.
3Adjusted earnings before interest, taxes, depreciation and amortization were negative C$820,000, compared with negative $597,000 a year earlier.
4Unrestricted cash was C$1.1 million on September 30, 2026, down from $3.8 million on December 31, 2025.

Medicure reported on November 19 results for the quarter ended September 30, 2026, posting a net loss of C$1.3 million, or C$0.13 per share, according to the company's disclosure prepared under International Financial Reporting Standards. The loss in the year-earlier period in 2025 was C$1.4 million, or C$0.13 per share. Net revenue was C$7.9 million, compared with C$8.2 million a year earlier. The figures put the latest quarter in the context of a year-on-year revenue decline and a limited improvement in the net loss, with loss per share unchanged. MCUJF closed at $2.51 on November 18, before the results were announced.

On a quarterly basis, Medicure had reported net revenue of C$7.4 million for the period ended June 30, 2026, versus C$6.7 million in the comparable quarter of 2025. Its net loss in that quarter was C$1.4 million, or C$0.14 per share, compared with a loss of $786,000, or $0.08 per share, a year earlier. In the third quarter of 2025, revenue reached C$8.2 million, up from C$5.2 million in the third quarter of 2024. In that comparison, the company moved from net income of $680,000 in 2024 to a loss of $1.4 million in 2025, or $0.13 per share. The comparisons show that revenue rose year over year in the second quarter, then declined in the third quarter compared with the year-earlier level.

Adjusted earnings before interest, taxes, depreciation and amortization were negative C$820,000 in the third quarter of 2026, versus negative $597,000 in the same period of 2025. The company said the main factor behind the decline was higher cost of goods sold after the addition of a recovery of previously written-off inventory. In the third quarter of 2025, Medicure attributed lower net income and adjusted performance to a decline in AGGRASTAT revenue and higher cost of goods and selling expenses. It added that growth in revenue from Marley Drug and the pharmacies it had acquired offset some of those pressures. The latest quarter's disclosure reflects the continued impact of cost of goods, while the factors cited a year earlier also included selling expenses and lower other income.

AGGRASTAT net sales were C$979,000 in the quarter, down from $1 million in the comparable period of 2025. Medicure attributed the decline to lower sales volume and pricing competition from generic tirofiban. By contrast, the pharmacy segment, which includes Marley Drug and the Gateway Medical and West Olympia pharmacies acquired by the company in 2025, recorded revenue of C$6.1 million, compared with C$6.4 million a year earlier. Segment revenue included $930,000 in ZYPITAMAG sales and $5.2 million in other pharmacy revenue. The results combine sales pressure on AGGRASTAT with lower pharmacy revenue than a year earlier, despite contributions from various products and activities to total revenue.

Research and development spending was C$676,000 in the third quarter, compared with $717,000 in the comparable quarter of 2025. The company's clinical and preclinical programs include a Phase 3 trial of candidate MC-1 for PNPO deficiency. On liquidity, unrestricted cash was C$1.1 million on September 30, compared with $3.8 million on December 31, 2025. Medicure attributed the decline mainly to working capital changes stemming from a decrease in accounts payable. The cash balance at the end of September places current funding alongside the operating loss and spending on development programs among the quarter's financial disclosures.

Medicure scheduled a call to discuss its quarterly results for November 23, 2026, at 8:30 a.m. Eastern time. MCUJF had closed at $2.51 in the November 18 session, according to EL7 data. The call follows the results announcement on November 19 and will allow the company to present performance details and discuss its components with participants. Key items disclosed by the company include the annual revenue decline, performance in the pharmacy and AGGRASTAT segments, and the drop in unrestricted cash since the end of 2025. Its research and development programs also include a Phase 3 trial of candidate MC-1 for PNPO deficiency.

Open on chart